Wanbury Limited faces Q3 FY25 revenue decline amid facility shutdown
Wanbury Limited, a pharmaceutical company with a strong presence in the active pharmaceutical ingredients (API) market and domestic branded formulations, has announced its financial results ... Read More
Wanbury Limited reports 11.6% growth in revenue for Q2 FY25, EBITDA surges 19.6%
Wanbury Limited, a leading pharmaceutical company with a global footprint in active pharmaceutical ingredients (APIs) and domestic branded formulations, has announced a stellar financial performance ... Read More